This risk seems to be most elevated in patients with CLL who have received previous antineoplastic treatment or who receive corticosteroids in conjunction with BTK inhibitor therapy, though it can be difficult to determine the true attributable risk given these other factors [65,66,91,92]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.